Comparative Pharmacology
Head-to-head clinical analysis: ETIDRONATE DISODIUM versus FOSAMAX PLUS D.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ETIDRONATE DISODIUM versus FOSAMAX PLUS D.
ETIDRONATE DISODIUM vs FOSAMAX PLUS D
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite crystals in bone, suppressing crystal dissolution and reducing bone turnover.
Alendronate, a bisphosphonate, inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite and interfering with the mevalonate pathway, leading to osteoclast apoptosis. Cholecalciferol (vitamin D3) promotes intestinal calcium absorption and bone mineralization.
Paget disease: 5-10 mg/kg/day orally, given as a single dose or divided every 12 hours, for up to 6 months; or 300 mg intravenously over at least 2 hours daily for 3 days. Heterotopic ossification: 20 mg/kg/day orally for 2 weeks pre- and 12 weeks post-surgery. Hypercalcemia of malignancy: 7.5 mg/kg intravenously over 4 hours daily for 3-7 days.
One tablet (alendronate 70 mg / cholecalciferol 2800 IU) orally once weekly.
None Documented
None Documented
Terminal half-life: 1-6 hours after single dose; prolonged to up to 2 weeks in bone due to slow release from hydroxyapatite.
Alendronate: Terminal half-life in bone is estimated at 10+ years due to slow release from the skeleton. Cholecalciferol: Half-life of 25-hydroxyvitamin D is ~15 days.
Renal: 30-50% of absorbed dose excreted unchanged in urine; biliary/fecal: minimal, with approximately 5% excreted in feces.
Alendronate: ~50% excreted unchanged in urine; remainder is taken up by bone and slowly eliminated. No biliary or fecal excretion of intact drug. Cholecalciferol: ~50% excreted in bile via feces; less than 1% in urine.
Category C
Category C
Bisphosphonate
Bisphosphonate